Laszlo Radvanyi

12.5k total citations · 2 hit papers
113 papers, 6.4k citations indexed

About

Laszlo Radvanyi is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Laszlo Radvanyi has authored 113 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Immunology, 72 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Laszlo Radvanyi's work include Immunotherapy and Immune Responses (57 papers), CAR-T cell therapy research (43 papers) and Immune Cell Function and Interaction (38 papers). Laszlo Radvanyi is often cited by papers focused on Immunotherapy and Immune Responses (57 papers), CAR-T cell therapy research (43 papers) and Immune Cell Function and Interaction (38 papers). Laszlo Radvanyi collaborates with scholars based in United States, Canada and Australia. Laszlo Radvanyi's co-authors include Patrick Hwu, Geok Choo Sim, Gordon B. Mills, R. G. Miller, Gregory Lizée, Chantale Bernatchez, Willem W. Overwijk, Patrick Hwu, Yufang Shi and Luis M. Vence and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Laszlo Radvanyi

111 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-L1 expression and prognostic impact in glioblastoma

2015 457 citations Jie Qing Chen, Caitlin Creasy et al. profile →
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

2018 405 citations Yan Lan, Dong Zhang et al. Science Translational Medicine profile →

Peers

Countries citing papers authored by Laszlo Radvanyi

Since Specialization

Citations

This map shows the geographic impact of Laszlo Radvanyi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laszlo Radvanyi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laszlo Radvanyi more than expected).

Fields of papers citing papers by Laszlo Radvanyi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laszlo Radvanyi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laszlo Radvanyi. The network helps show where Laszlo Radvanyi may publish in the future.

Co-authorship network of co-authors of Laszlo Radvanyi

This figure shows the co-authorship network connecting the top 25 collaborators of Laszlo Radvanyi. A scholar is included among the top collaborators of Laszlo Radvanyi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laszlo Radvanyi. Laszlo Radvanyi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas 2024 ·Frontiers in Immunology ·(unknown), Melanie Thiede, (unknown), (unknown), Leopold Flohé, (unknown), (unknown), Valentina Evdokimova, Laszlo Radvanyi, Israh Akhtar, (unknown), Franziska Auer, Sebastian Johannes Schober, Julia Hauer, Uwe Thiel, (unknown)	1
2	Extracellular Vesicles and Their Applications in Tumor Diagnostics and Immunotherapy 2024 ·Cells ·Scott Strum, Valentina Evdokimova, Laszlo Radvanyi, Anna Spreafico	3
3	Current State of Immunotherapy and Mechanisms of Immune Evasion in Ewing Sarcoma and Osteosarcoma 2022 ·Cancers ·Valentina Evdokimova, (unknown), Laszlo Radvanyi, Stefan Burdach	30
4	Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β breakdown → 2018 ·Science Translational Medicine ·Yan Lan, Dong Zhang, Chunxiao Xu, Kenneth W. Hance, Bo Marelli, Jin Qi, Huakui Yu, Guozhong Qin, Aroop Sircar, Vivian M. Hernández, Molly H. Jenkins, Rachel E. Fontana, Amit Deshpande, George Locke, Helen Sabzevari, Laszlo Radvanyi, Kin-Ming Lo	405
5	Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter 2017 ·Clinical Cancer Research ·Krit Ritthipichai, Cara Haymaker, (unknown), (unknown), Xiaohui Yi, Minying Zhang, (unknown), Luis M. Vence, Jason Roszik, Yared Hailemichael, Willem W. Overwijk, Navin Varadarajan, Roza Nurieva, Laszlo Radvanyi, Patrick Hwu, Chantale Bernatchez	54
6	4-1BB–Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells 2017 ·Cancer Immunology Research ·Michiko Harao, Marie-Andrée Forget, Jason Roszik, Hui Gao, Gildy V. Babiera, Savitri Krishnamurthy, Jessica Chacon, Shumin Li, Elizabeth A. Mittendorf, Sarah M. DeSnyder, (unknown), Chantale Bernatchez, Naoto T. Ueno, Laszlo Radvanyi, Luis M. Vence, Cara Haymaker, James M. Reuben	49
7	Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models 2017 ·Clinical Cancer Research ·Chunxiao Xu, Yanping Zhang, Alex Rolfe, Vivian M. Hernández, (unknown), (unknown), Bo Marelli, Guozhong Qin, Jin Qi, Hong Wang, Huakui Yu, Robert M. Tighe, Kin-Ming Lo, Jessie M. English, Laszlo Radvanyi, Yan Lan	58
8	Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth 2017 ·Clinical Cancer Research ·Ming Li, Laszlo Radvanyi, Bingnan Yin, Kiera Rycaj, Jia Li, (unknown), Kevin Lin, Yue Lu, Jianjun Shen, David Chang, Donghui Li, Gary L. Johanning, Feng Wang‐Johanning	98
9	IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation 2016 ·Cancer Immunology Research ·Geok Choo Sim, Chengwen Liu, Ena Wang, Hui Liu, Caitlin Creasy, Zhimin Dai, Willem W. Overwijk, Jason Roszik, Francesco M. Marincola, Patrick Hwu, (unknown), Laszlo Radvanyi	36
10	BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma 2015 ·Cancer Immunology Research ·Sherille D. Bradley, Zeming Chen, Brenda Melendez, Amjad H. Talukder, Jahan S. Khalili, Tania Rodríguez-Cruz, Shujuan Liu, Mayra Whittington, Wanleng Deng, Fenge Li, Chantale Bernatchez, Laszlo Radvanyi, Michael A. Davies, Patrick Hwu, Gregory Lizée	124
11	Cytotoxicity of Human Endogenous Retrovirus K–Specific T Cells toward Autologous Ovarian Cancer Cells 2014 ·Clinical Cancer Research ·Kiera Rycaj, Joshua B. Plummer, Bingnan Yin, Ming Li, (unknown), Laszlo Radvanyi, Lois M. Ramondetta, Kevin Lin, Gary L. Johanning, Dean G. Tang, Feng Wang‐Johanning	82
12	Manipulating the Tumor Microenvironment Ex Vivo for Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy 2014 ·Clinical Cancer Research ·Jessica Chacon, Amod A. Sarnaik, Jie Qing Chen, Caitlin Creasy, (unknown), John Robinson, Jeffrey S. Weber, Patrick Hwu, Shari Pilon‐Thomas, Laszlo Radvanyi	48
13	Detection and Characterization of a Novel Subset of CD8+CD57+ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype 2012 ·Clinical Cancer Research ·Richard C. Wu, Shujuan Liu, Jessica Chacon, Sheng Wu, Yufeng Li, Pariya Sukhumalchandra, (unknown), Jeffrey J. Molldrem, Patrick Hwu, Hanspeter Pircher, Gregory Lizée, Laszlo Radvanyi	19
14	PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines 2012 ·Cancer Research ·Weiyi Peng, Chengwen Liu, Chunyu Xu, Yanyan Lou, Jieqing Chen, Yan Yang, Hideo Yagita∥, Willem W. Overwijk, Gregory Lizée, Laszlo Radvanyi, Patrick Hwu	340
15	A New Approach to Simultaneously Quantify Both TCR α- and β-Chain Diversity after Adoptive Immunotherapy 2012 ·Clinical Cancer Research ·Minying Zhang, Sourindra N. Maiti, Chantale Bernatchez, Helen Huls, Brian Rabinovich, Richard E. Champlin, Luis M. Vence, Patrick Hwu, Laszlo Radvanyi, Laurence J.N. Cooper	15
16	BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency 2012 ·Clinical Cancer Research ·David S. Hong, Luis M. Vence, Gerald S. Falchook, Laszlo Radvanyi, Chengwen Liu, Vicki Goodman, Jeffery J. Legos, (unknown), (unknown), Razelle Kurzrock, Gregory Lizée, Patrick Hwu	82
17	Costimulation through 4-1BB/CD137 improves the expansion and function of CD8+ melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy (66.21) 2011 ·The Journal of Immunology ·Jessica Chacon, Yi‐Jun Wang, Richard C. Wu, Patrick Hwu, Laszlo Radvanyi	1
18	Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells 2010 ·Cancer Research ·Natalia Martín‐Orozco, Yufeng Li, Yi‐Jun Wang, Shijuan Liu, Patrick Hwu, Yong‐Jun Liu, Chen Dong, Laszlo Radvanyi	109
19	Human Endogenous Retrovirus K Triggers an Antigen-Specific Immune Response in Breast Cancer Patients 2008 ·Cancer Research ·Feng Wang‐Johanning, Laszlo Radvanyi, Kiera Rycaj, Joshua B. Plummer, Peisha Yan, K. Jagannadha Sastry, Chandrika J. Piyathilake, Kelly K. Hunt, Gary L. Johanning	161
20	Effect of Serum and Antioxidants on the Immunogenicity of Protein Kinase C-Activated Chronic Lymphocytic Leukemia Cells 2004 ·Journal of Immunotherapy ·(unknown), Yonghong Shi, (unknown), Jelena Tomić, David Cervi, Liwei He, (unknown), Mark DeBenedette, Andre C. Schuh, Jeremy L. Baryza, Paul A. Wender, Laszlo Radvanyi, David Spaner	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact